Piracetam
A prototypical 'racetam' nootropic. Prescription drug in much of Europe, NOT FDA-approved in the US — sold here as an unregulated 'research chemical.' Despite a half-century of marketing as a smart drug, Cochrane reviews find no evidence for dementia, cognitive impairment, or routine post-stroke use. The strongest signal (still modest) is for vertigo. Cognitive-enhancement-in-healthy-people is mechanism-only — no robust trial evidence.
Research compound — not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only — talk to a clinician before considering it.
Quick decision guide
May help most
Adults with chronic vertigo (only under a neurologist's care, and only where piracetam is a legally prescribed medication). NOT a recommended use case for healthy 'biohackers.'
Common dosing range
Studied at 1.6–4.8 g/day in 2–3 divided doses for vertigo and post-stroke trials. Always with physician supervision.
When to expect effects
Weeks for vestibular endpoints; cognitive endpoints largely null in well-controlled trials.
Watch out for
Not FDA-approved as a drug OR supplement in the US. Consumer product quality is unregulated. May increase bleeding risk and is excreted unchanged by kidneys — accumulates in renal impairment.
Evidence snapshot
What is it
Piracetam is the original racetam, synthesized in 1964 by Belgian chemist Corneliu Giurgea, who coined the term 'nootropic.' It is a cyclic derivative of GABA used in many countries as a prescription medication for cognitive impairment, dementia, myoclonus, and certain childhood conditions. In the US, the FDA does not recognize piracetam as a dietary supplement ingredient.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Chronic vertigo Limited Evidence | Reduction in vertigo episode frequency vs placebo reported in smaller trials; effect magnitude inconsistent | Adults with chronic central vertigo under specialist care, where piracetam is a legal prescription option | Weeks of regular dosing in trials |
Dementia and age-related cognitive impairment Mixed Evidence | No statistically significant effect on cognitive outcomes in the Cochrane synthesis | None established by current evidence | Not established — even long trials (months) failed to show benefit |
Acute ischemic stroke Mixed Evidence | No proven benefit; non-significant trend toward harm in mortality | None — modern acute stroke care is thrombolysis/thrombectomy, not piracetam | Not applicable |
Cognitive enhancement in healthy adults ('nootropic' use) Mixed Evidence | No robust trial evidence of improved cognition in healthy adults | None established by clinical evidence | Not established for healthy-adult cognition |
Chronic vertigo
- Effect
- Reduction in vertigo episode frequency vs placebo reported in smaller trials; effect magnitude inconsistent
- Best fit
- Adults with chronic central vertigo under specialist care, where piracetam is a legal prescription option
- Time
- Weeks of regular dosing in trials
Dementia and age-related cognitive impairment
- Effect
- No statistically significant effect on cognitive outcomes in the Cochrane synthesis
- Best fit
- None established by current evidence
- Time
- Not established — even long trials (months) failed to show benefit
Acute ischemic stroke
- Effect
- No proven benefit; non-significant trend toward harm in mortality
- Best fit
- None — modern acute stroke care is thrombolysis/thrombectomy, not piracetam
- Time
- Not applicable
Cognitive enhancement in healthy adults ('nootropic' use)
- Effect
- No robust trial evidence of improved cognition in healthy adults
- Best fit
- None established by clinical evidence
- Time
- Not established for healthy-adult cognition
Evidence for 4 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Chronic vertigo
Disease adjunctOlder European randomized trials suggest piracetam may reduce frequency of vertigo episodes and improve compensation after a vestibular insult, and vertigo is one of the indications described in Winblad's 2005 pharmacology review. Trials are small, heterogeneous, and largely from countries where piracetam is a prescribed drug; no Cochrane-grade synthesis has confirmed a robust effect. This is piracetam's least-weak indication but it is still not first-line.
Bottom line: The strongest of piracetam's weak indications. Discuss with an ENT or neurologist; don't self-medicate.
Dementia and age-related cognitive impairment
Mechanism onlyThe 2001 Cochrane review (Flicker & Grimley Evans, PMID 11405971) included multiple placebo-controlled trials and concluded that published evidence does not support piracetam use in dementia or cognitive impairment. No benefit was found on MMSE, memory, or dependency endpoints. Some 'global impression of change' improvements were noted, but these are subjective and prone to bias. Most trials are old and methodologically below current standards; publication bias is suspected.
Bottom line: Don't use it for dementia. Approved therapies (donepezil, rivastigmine, galantamine, memantine) have modest but real evidence; piracetam doesn't.
Acute ischemic stroke
Mechanism onlyThe 2012 Cochrane review (Ricci et al., PMID 22972044) pooled 3 RCTs (n=1,002) and found a non-significant trend toward increased early death (OR 1.32, 95% CI 0.96–1.82) and no benefit on functional outcomes. The authors explicitly conclude available evidence does not support routine use of piracetam in acute ischemic stroke.
Bottom line: Not standard care. Modern stroke pathways (alteplase, mechanical thrombectomy) are evidence-based; piracetam is not.
Cognitive enhancement in healthy adults ('nootropic' use)
Mechanism onlyThis is piracetam's most-marketed use and its least-supported. There are essentially no rigorous randomized controlled trials of piracetam improving cognition (working memory, executive function, attention) in healthy adults. Mechanistic claims involve membrane fluidity modulation, AMPA receptor positive modulation, and improved interhemispheric communication — interesting biochemistry that has not translated to measurable cognitive gains in healthy people.
Bottom line: If you're buying piracetam to make yourself smarter, you're spending money on hype. The mechanism is real; the human cognitive benefit is not.
How it works
How to take it
What to track
Bottom line: If your doctor prescribed it, follow their dose. If you're considering it as a self-administered nootropic, the evidence doesn't support that use.
4 commercial forms
Compare the main delivery options and what they’re best suited for.
Piracetam capsules / tablets (prescription, EU/UK)
Quality-controlledPharmacy-dispensed pharmaceutical-grade piracetam (brand names include Nootropil and Lucetam in Europe). 800 mg or 1200 mg tablets are typical. The only form with guaranteed identity and purity.
Reference quality-controlled form.
Piracetam powder (consumer 'nootropic')
Quality not guaranteedSold in bulk by nootropics retailers, particularly in the US where piracetam is not approved as a drug or supplement. Identity and purity vary widely. Demand a recent third-party HPLC/NMR analysis from any vendor; even then, supply quality fluctuates.
Same active compound when authentic; verification is the issue.
Piracetam oral solution
Liquid prescriptionEuropean pharmacy formulation. Useful for elderly patients with swallowing difficulty or pediatric dosing.
Faster Tmax than tablets; total exposure similar.
Piracetam IV (hospital use)
Acute/inpatientUsed in some European hospitals for acute neurologic indications (myoclonus, post-stroke). Not relevant to consumer use.
Bypasses oral absorption entirely.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Bleeding — piracetam decreases platelet aggregation and may potentiate the effect of anticoagulants and antiplatelets. Stop at least 7 days before any planned surgery and discuss with your prescriber.
Accumulation in kidney impairment — piracetam is cleared almost entirely renally. Doses must be reduced in renal impairment; contraindicated in severe renal failure.
Quality and purity of consumer 'research chemical' piracetam are unverified — third-party testing of nootropic products has found inconsistent potency and contamination.
Who should avoid it
- People with kidney impairment (CrCl <60 mL/min), especially severe renal failure (contraindicated).
- People on warfarin, DOACs, antiplatelets, or about to undergo surgery — bleeding risk.
- People with Huntington's chorea — piracetam may exacerbate involuntary movements.
- Pregnant or breastfeeding women — no human safety data; not recommended.
- US consumers seeking it as a supplement — it is an unapproved drug; no quality control.
Pregnancy & breastfeeding
Human safety data are inadequate. Animal studies have not shown clear teratogenicity, but with no human evidence and no compelling indication, piracetam should not be used during pregnancy or breastfeeding.
Bottom line: Side effects (insomnia, irritability) are the usual reasons for discontinuation. The biggest hidden risk is the unregulated US supply chain — purity and dose are not guaranteed.
Interactions
Piracetam has antiplatelet activity and can additively increase bleeding risk with anticoagulants and antiplatelets. Stop ≥7 days before surgery.
Case reports describe confusion, irritability, and sleep disturbance when piracetam is combined with thyroid hormone. Mechanism unclear; monitor closely if combined.
Piracetam may interact with antiepileptic regimens; monitor seizure control and levels if added to anticonvulsant therapy.
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is piracetam legal?⌄
It is a prescription medication in many European countries but not approved or recognized in the US as a drug or supplement. Legal status varies by country.
Does piracetam make you smarter?⌄
It has shown modest benefits in cognitively impaired elderly patients. Evidence for cognitive enhancement in healthy young adults is weak and inconsistent.
What is the loading dose?⌄
Some users start with higher doses (4-9 g per day) for the first 1-2 days, then taper to maintenance. Clinical evidence for this approach is limited.
Should I take choline with piracetam?⌄
Many users find that co-supplementing with choline sources (alpha-GPC, CDP-choline) reduces racetam-related headaches and may improve effects.
Is piracetam safe long-term?⌄
Clinical use spans decades in some countries with a good safety profile. Long-term outcomes in healthy users for cognitive enhancement are less documented.
References by claim
Dementia and age-related cognitive impairment
Flicker & Grimley Evans, 2001 — Cochrane Database of Systematic Reviews (2001) link
Acute ischemic stroke
Ricci et al., 2012 — Cochrane Database of Systematic Reviews (2012) link
Safety
U.S. FDA Warning Letter, 2019 — FDA Center for Drug Evaluation and Research (2019) link
Chronic vertigo
Winblad, 2005 — CNS Drug Reviews (2005) link
Track Piracetam with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research — much of it preclinical or early-stage — not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.